Lexaria Bioscience Corp improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods. The Company's technology can be applied to ingestible product formats such as foods, beverages, oral suspensions, tablets, and capsules. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.

Current Report (Form 8-K | Period ending 2024-12-16)

424B3 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lexaria Bioscience (LEXX US)

Current Report (Form 8-K | Period ending 2024-12-16)

424B3 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Annual Report (Form 10-K | Period ending 2024-08-31)

Current Report (Form 8-K | Period ending 2024-10-16)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)